Related Experiment Videos
Expression of bcl-2, bcl-x, bax and bak in renal parenchyma, oncocytomas and renal cell carcinomas
1Institut für Klinische Pathologie, Allgemeines Krankenhaus Wien, Osterreich.
Abstract:
Proteins of the bcl-2 family are important regulators of programmed cell death. Alterations in the expression of these proteins may contribute to the progression of cancer. Expression of bcl-2, bcl-x, bax and bak was investigated by immunohistochemistry and Western-blotting of regular and alterated renal parenchyma as well as in 57 renal cell carcinomas. Bcl-2, bcl-x and in part bax were found to be overexpressed in inflammed renal parenchyma, whereas atrophic tubuli predominantly stained for bcl-2 and to a lesser degree for bcl-x and bax. Only little bak expression was detected in alterated tubuli. Moderate to strong expression for bcl-2, bcl-x, bax and bak was found in 24, 38, 2 and 13 of 57 carcinomas, respectively. Bcl-2, bcl-x, bax and bak expression were correlated to tumor type. Chromophilic carcinomas stained stronger for bcl-2, bcl-x and bax, whereas chromophobic carcinomas stained stronger for bcl-x, bax and bak compared to clear cell carcinomas. Expression of bak correlated with that of bcl-x and with an unfavorable histology as indicated by nuclear grading in these tumors. Our findings suggest that expression of bcl-2 and bcl-x may be important for cell survival only in a subset of renal cell carcinomas, and that the anti-apoptotic effect of these proteins appears to be frequently bypassed possibly by other factors impeding programmed cell death.
Insights
Proteins regulating cell death, including Bcl-2, show altered expression in kidney cancer. While some proteins are overexpressed in tumors, their anti-apoptotic effects may be bypassed, suggesting complex roles in cancer progression.
Area of Science:
- Molecular Biology
- Oncology
- Cell Biology
Background:
- Proteins of the BCL-2 family are key regulators of programmed cell death (apoptosis).
- Dysregulation of BCL-2 family protein expression is implicated in cancer development and progression.
- Understanding these proteins' roles in renal cell carcinoma (RCC) is crucial for therapeutic strategies.
Purpose of the Study:
- To investigate the expression patterns of BCL-2, BCL-X, BAX, and BAK proteins in normal and altered renal parenchyma.
- To analyze the expression of these apoptosis regulators in 57 cases of renal cell carcinoma (RCC).
- To correlate protein expression with RCC subtypes and histological features.
Main Methods:
- Immunohistochemistry was employed to assess protein expression in tissue samples.
- Western blotting was used to quantify protein levels.
- Expression data were correlated with tumor type and nuclear grading in RCC.
Main Results:
- BCL-2, BCL-X, and BAX were overexpressed in inflamed renal parenchyma; atrophic tubules showed predominant BCL-2 and some BCL-X and BAX staining.
- Significant expression of BCL-2, BCL-X, BAX, and BAK was detected in 24%, 38%, 2%, and 13% of RCCs, respectively.
- Specific staining patterns for BCL-2, BCL-X, BAX, and BAK varied across chromophilic, chromophobic, and clear cell RCC subtypes.
- BAK expression correlated with BCL-X and unfavorable histology (nuclear grading).
Conclusions:
- BCL-2 and BCL-X expression may be vital for cell survival in a subset of RCCs.
- The anti-apoptotic function of BCL-2 and BCL-X might be circumvented by other mechanisms in RCC.
- Further research is needed to elucidate the complex interplay of apoptosis regulators in RCC pathogenesis.